Liver-Chip Hepatotoxicity Assay
Standard protocol for assessing drug-induced liver injury using liver-chip platforms. Measures ALT, albumin, and bile markers.
⏱️ 7-14 days
📊 6+ endpoints
Liver
Toxicity
OoC
Gut Barrier Permeability Assay
Measure intestinal barrier integrity using TEER and fluorescent marker passage in gut-chip or transwell systems.
⏱️ 5-7 days
📊 3 endpoints
Intestine
Barrier
TEER
BBB Transport Assessment
Blood-brain barrier model for assessing CNS drug penetration. Includes endothelial, astrocyte, and pericyte co-culture.
⏱️ 10-14 days
📊 5 endpoints
Brain
BBB
Transport
Cardiac Contractility Assay
Assess cardiotoxicity using iPSC-derived cardiomyocytes. Measures beat rate, FPD, and arrhythmia events.
⏱️ 7-10 days
📊 4 endpoints
Cardiac
Safety
MEA
Kidney Proximal Tubule Toxicity
Nephrotoxicity assessment using kidney-chip. Measures KIM-1, NAG, and transporter function.
⏱️ 7-14 days
📊 5 endpoints
Kidney
Toxicity
OoC
Tumor Organoid Drug Response
Patient-derived tumor organoid assay for personalized drug sensitivity testing. ATP-based viability readout.
⏱️ 14-21 days
📊 IC50 curves
Oncology
Organoid
Personalized
Lung Air-Liquid Interface Culture
Establish differentiated airway epithelium at ALI for respiratory drug testing and toxicology.
⏱️ 21-28 days
📊 4 endpoints
Lung
ALI
Respiratory
Skin Model Irritation Assay
3D skin equivalent for dermal irritation and toxicity testing. OECD TG 439 compatible.
⏱️ 5-7 days
📊 2 endpoints
Skin
Irritation
OECD